A competitive enzyme-linked immunosorbent assay (C-ELISA), based on a truncated E2 recombinant protein of the Alfort/187 strain of classical swine fever virus (CSFV) and a specific monoclonal antibody M1669, was evaluated using 2,000 sera from clinically healthy pigs in Canada (a CSFV-free country) and sera from experimentally infected pigs. The relative specificity and sensitivity of the C-ELISA were 100% and 86%, respectively, at a cutoff of 25% inhibition using negative and positive pig sera, as defined by the neutralizing peroxidase-linked assay (NPLA). A kappa value of 0.91 was obtained, indicating an excellent level of agreement between the NPLA and the C-ELISA. When sera from 120 infected pigs were used in the test at Ն21 days postinfection, the sensitivity of the C-ELISA and the kappa value increased to 97% and 0.98, respectively. This C-ELISA will be useful when a large number of samples must be tested, as could occur during a disease outbreak or for surveillance or prevalence studies.
Classical swine fever (CSF) is a highly contagious disease of domestic pigs and wild boars. It has gained new prominence among viral infectious diseases of swine because of the recent outbreak in Europe, leading to the slaughter of millions of pigs. In The Netherlands alone, almost 11 million pigs were destroyed in the course of the epidemic. 4 The economic impact of the disease on a national pig industry can be enormous. The total financial impact of the outbreak in The Netherlands was about US $2.3 billion. 9 CSF has the potential for serious and rapid spread if introduced into North America. Clinical signs are variable, and virulent strains can cause high morbidity and mortality. Subacute and chronic forms of CSF can spread without immediate detection because of less dramatic clinical signs.
Eradication programs against CSF are based on rapid identification of outbreaks, slaughter of infected herds, control of pig and pork movements within infected regions, and forward and backward tracing of disease spread. Current methods for diagnosis of CSF rely on the detection of antigen in frozen tissue sections using the fluorescent antibody tissue section technique and on isolation of the virus in cell culture. Serologic techniques include the fluorescent antibody virus neutralization test (FAT-SN), enzyme-linked immunosorbent assay (ELISA), complex-trapping-blocking (CTB) ELISA, and neutralizing peroxidase-linked assay (NPLA). Several ELISA techniques for antibody detection, such as the blocking ELISA using whole virus as antigen, 7 the indirect ELISA, 10 or the CTB ELISA have been described.
The objective of this study was to evaluate a competitive ELISA (C-ELISA) for the serologic diagnosis of CSF by defining the diagnostic characteristics of this assay. Sera collected from experimentally infected pigs were tested, and results were compared with those of a standard virus neutralization test.
Primers targeting 674 bp of the E2 gene of the CSF virus From the National Centre for Foreign Animal Disease, 1015 Arlington St., Suite T2300, Winnipeg, Manitoba R3E 3M4, Canada (Clavijo, Riva, Zhou), and the Animal Diseases Research Institute, 3851 Fallowfield Rd., Nepean, Ontario K2H 8P9, Canada (Lin).
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(CSFV) envelope glycoprotein were used in a reverse transcription polymerase chain reaction (RT-PCR). The primers were located at positions 2,441-2,460 (5Ј-GGA-TCCCAGCTAGCCTGCAAGGAAGA-3Ј) and 3,083-3,102 (5Ј-AAGCTTGGGTAGTGTGGGAGTCCGTC-3Ј) of the published sequence of CSFV strain Alfort/187. 14 RT-PCR and post-PCR analyses were performed as previously described. 6 The 674-bp gene fragment corresponding to the truncated E2 protein of CSFV was amplified and ligated into the pCR3 vector, a according to instructions from the supplier. The fragment was then subcloned in frame into the BamHI and HindIII restriction sites of the plasmid pET30a(ϩ) b and transformed into Escherichia coli strain BL21(DE3)pLysS. A clone containing the inserted DNA in the correct orientation was designated pETE2AB. Protein expression was performed according to instructions from the supplier. b The recombinant E2 protein was purified by using nickel-nitrilotriacetic acid metal-affinity chromatography. c The E2 protein was chosen as primary antigen for the ELISA because serum antibodies induced by pestivirus infections are directed mainly against the structural proteins. In addition, this glycoprotein elicits a strong immunologic response in infected animals. 21 The immunogenicity of the recombinant protein either in the crude E. coli extract or as purified recombinant protein was tested by western blotting as described previously. 15, 19 Monoclonal antibodies (MAbs) were also produced using a purified recombinant E2 protein as antigen according to established procedures. 16, 21 The C-ELISA using E2 recombinant protein was based on a method described elsewhere. 1 In each plate a strong positive, a weak positive, and negative controls were used. The optical density (OD) was determined at 414 nm on an automated ELISA plate reader. d Results were expressed as percentage of inhibition and were derived from the mean OD values for each sample by the following formula: percentage of inhibition ϭ [1-(OD test sample)/(OD target control)] ϫ 100%. MAb M1669 in diluent buffer (without serum) was used as the target control. NPLA was performed as described elsewhere, 18 using 100 TCID 50 of CSFV strain Alfort/187. The FAT-SN was per- formed in microtiter plates using PK-15 cells. Neutralizing antibodies were detected as described elsewhere. 13 Purified E2 recombinant protein was diluted in carbonate buffer and used as coating antigen in microtiter plates. The optimal conditions for antigen concentration and serum dilutions were established by checkerboard titration. The cutoff value for the assay, i.e., the percentage of inhibition limit that determines the negative or positive reactor status of a given animal, was based on results of 2,000 pig sera obtained from a CSFV-free Canadian population (Fig. 1) .
A total of 929 NPLA-negative and 136 NPLA-positive serum samples were also tested by C-ELISA to estimate the relative sensitivity, specificity, and agreement of the recombinant protein-based C-ELISA with NPLA. Specificity and sensitivity of 100% and 86% were obtained, respectively. A kappa value of 0.91 was obtained, indicating an excellent level of agreement between these 2 tests (Table 1 ). If animals were tested Ն3 weeks after infection with the C-ELISA, the number of false negatives was reduced from 14% to 2.5% and the sensitivity increased to 97% with a kappa value of 0.98. The above observation was made using a receiver operating characteristic (ROC) analysis by plotting sensitivity rates against false-positive rates, testing samples from pigs on different days postinfection (Fig. 2) . The ROC curve shows an increase in the sensitivity of the test to 92% when pigs were tested Ͼ15 days postinfection (dpi). A maximum sensitivity of 97% was achieved when the animals had been infected for Ͼ4 weeks. The areas under the ROC curve were 0.94, 0.98, and 0.99 for samples taken from pigs at Ͼ0, Ͼ15, and Ͼ30 dpi, respectively.
The occurrence of false-positive and false-negative results for samples on different days postinfection was evaluated in an error rate curve (Fig. 3) . The false-positive rate did not change. However, as expected, more false-negative results were obtained earlier in the course of infection. The lowest false-negative rate (3%) was obtained for samples from animals tested at Ͼ30 dpi. Figure 4 shows the linear regression of the percentage of inhibition obtained by the recombinant C-ELISA and NPLA. The comparison of the C-ELISA with NPLA using 136 positive NPLA serum samples gave an R 2 value of 0.71. This coefficient of determination value indicates a good level of agreement between these 2 tests.
Several ELISAs for the detection of antibodies to CSFV have been described, and some are commercially available. Determination of sensitivity and specificity is very important for the evaluation of a diagnostic test. In countries free of CSFV or countries expecting to be internationally recognized as being free of the disease, the specificity is more important to avoid false-positive results, which may have serious consequences. For this study, a cutoff value that results in high specificity was selected. However, this C-ELISA could also be used in CSF outbreaks, where high sensitivity is required.
The NPLA was used as the ''gold standard'' to evaluate the performance of the C-ELISA. The NPLA has been reported to be as sensitive as the microplaque reduction test. It can be used to detect antibodies to CSFV in 70% -80% of pigs 3 weeks after experimental infection. 18 The present results indicate that the relative sensitivity and specificity of this C-ELISA are comparable to those reported by others. 11, 12 The Office International des Epizooties recognizes the value of using serologic tests, particularly after 5 weeks in herds suspected of being infected with CSFV. In the present study, sensitivity and specificity of 97% and 100%, respectively, were obtained when pigs were tested at 3 weeks postinfection. Similar results were obtained with a recent CTB (DIF-CTB-A1) ELISA 20 ; pigs experimentally infected with CSFV were unequivocally detected at 21 dpi. In CSFV transmission studies in The Netherlands during the 1997 outbreak, the probability of a positive serologic test result was determined to be a function of the time elapsed since infection of an individual pig. 17 The average number of days between infection and seroconversion was estimated at 18.45. The probability of a diagnostic test detecting a seropositive animal is about 60% at 20 dpi and 100% at 30 dpi. 17 An ROC plot was obtained by calculating the sensitivity and specificity for each observed value. 8 Results of this curve indicate that testing pigs 3-4 weeks after infection allows adequate discrimination between infected and noninfected animals. The accuracy of this test was confirmed by analyzing the area under the ROC curve. Values between 0.94 and 0.99 were obtained, indicating a high probability that a random animal with CSF will have a higher percentage of inhibition (positivity) than will a random animal without CSF. 5 When the ROC curves of test results obtained from pigs tested after 1, 2, or 4 weeks postinfection were compared, better discriminatory power was obtained when pigs were tested 3-4 weeks postinfection.
Because maximal sensitivity is required for an assay to be used for monitoring CSF during an outbreak, the cutoff value of the C-ELISA can be reduced to 10-15% with the shift on the specificity of the assay to 88-95%. However, these changes will result in an increase in the number of false positives. In view of the serious consequences of reporting a sample as positive, a confirmatory test such as NPLA should be used. However, as accepted with other ELISAs, results should be evaluated by considering the herd of origin and not only the results of testing a single serum sample from an individual pig. 12 During the CSF epizootic of 1997-1998 in The Netherlands, Ͼ2 million samples for virus isolation or serum antibody tests were processed. 3 Of the 429 outbreaks, 84% were detected by antigen/virus detection systems. Serologic testing led to the detection of only 13.5% of the total number of outbreaks. Serologic testing was needed to test millions of healthy pigs that required screening for the presence of CSF antibody. Positive samples were usually retested before a decision was made regarding the presence of CSFV on the farm. 3 The results of the present study indicate that the C-ELISA is a simple, rapid, and reliable test for the detection of CSFVspecific antibodies in serum. The C-ELISA results are comparable to those of the NPLA. Although the C-ELISA was not as sensitive as the NPLA, an increase in the herd sample size can ensure the detection of infected pigs even with a low prevalence of the disease. Therefore, the relatively low sensitivity of the C-ELISA, as compared with NPLA, is of minor importance when an adequate sample size is available. Thus, the C-ELISA may be useful tool in large-scale screening and eradication programs for CSF.
